메뉴 건너뛰기




Volumn 13, Issue 4, 2012, Pages 505-508

New therapeutic pathways in the RAS

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; ANGIOTENSIN[1-7]; AZILSARTAN; CGEN 856; DIMINAZENE ACETURATE; EMA 401; ENDOTHELIN A RECEPTOR ANTAGONIST; MEMBRANE METALLOENDOPEPTIDASE; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; NITRIC OXIDE; RE 021; UNCLASSIFIED DRUG; VALSARTAN;

EID: 84870030184     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312466519     Document Type: Article
Times cited : (33)

References (33)
  • 2
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
    • Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 ; 342: 145-153
    • (2000) N Engl J Med , vol.342 , pp. 145-153
    • Yusuf, S.1    Sleight, P.2    Pogue, J.3
  • 3
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
    • Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002 ; 359: 995-1003
    • (2002) Lancet , vol.359 , pp. 995-1003
    • Dahlöf, B.1    Devereux, R.B.2    Kjeldsen, S.E.3
  • 5
    • 42649115768 scopus 로고    scopus 로고
    • Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)- Mas axis
    • Santos RAS, Ferreira AJ, Simões E, et al. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008 ; 93: 519-527
    • (2008) Exp Physiol , vol.93 , pp. 519-527
    • Santos, R.A.S.1    Ferreira, A.J.2    Simões, E.3
  • 6
    • 84865642487 scopus 로고    scopus 로고
    • Critical evaluation of the efficacy and tolerability of azilsartan
    • De Caterina AR, Harper AR, Cuculi F. Critical evaluation of the efficacy and tolerability of azilsartan. Vasc Health Risk Manag. 2012 ; 8: 299-305
    • (2012) Vasc Health Risk Manag , vol.8 , pp. 299-305
    • De Caterina, A.R.1    Harper, A.R.2    Cuculi, F.3
  • 7
    • 84868668210 scopus 로고    scopus 로고
    • TRV120027, a novel β-arrestin biased ligand at the angiotensin II type i receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure
    • Boerrigter G, Soergel DG, Violin JD, et al. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail. 2012 ; 5: 627-634
    • (2012) Circ Heart Fail , vol.5 , pp. 627-634
    • Boerrigter, G.1    Soergel, D.G.2    Violin, J.D.3
  • 8
    • 84871074661 scopus 로고    scopus 로고
    • Trevena Inc accessed 18 September 2012
    • Trevena Inc, http://www.trevenainc.com (2010, accessed 18 September 2012).
    • (2010)
  • 9
    • 84870052689 scopus 로고    scopus 로고
    • Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics
    • Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics. Eur Heart J. 2012 ;:
    • (2012) Eur Heart J
    • Mangiafico, S.1    Costello-Boerrigter, L.C.2    Andersen, I.A.3
  • 10
    • 84871064839 scopus 로고    scopus 로고
    • Retrophin LLC accessed 18 September 2012
    • Retrophin LLC, http://www.retrophin.com (2011, accessed 18 September 2012).
    • (2011)
  • 11
    • 65549143348 scopus 로고    scopus 로고
    • Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties
    • Martelli A, Breschi MC, Calderone V. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties. Curr Pharm Des. 2009 ; 15: 614-636
    • (2009) Curr Pharm des , vol.15 , pp. 614-636
    • Martelli, A.1    Breschi, M.C.2    Calderone, V.3
  • 12
    • 84871047168 scopus 로고    scopus 로고
    • NicOx accessed 18 September 2012
    • NicOx, http://www.nicox.com (2012, accessed 18 September 2012).
    • (2012)
  • 13
    • 0032973878 scopus 로고    scopus 로고
    • Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition
    • Miura S, Karnik SS. Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J Hypertens. 1999 ; 17: 397-404
    • (1999) J Hypertens , vol.17 , pp. 397-404
    • Miura, S.1    Karnik, S.S.2
  • 14
    • 7444240177 scopus 로고    scopus 로고
    • Synthesis and AT2 receptor-binding properties of angiotensin II analogues
    • Rosenström U, Sköld C, Lindeberg G, et al. Synthesis and AT2 receptor-binding properties of angiotensin II analogues. J Pept Res. 2004 ; 64: 194-201
    • (2004) J Pept Res , vol.64 , pp. 194-201
    • Rosenström, U.1    Sköld, C.2    Lindeberg, G.3
  • 16
    • 84871073913 scopus 로고    scopus 로고
    • Lanthio Pharma accessed 18 September 2012
    • Lanthio Pharma, http://www.lanthiopharma.com (2012, accessed 18 September 2012).
    • (2012)
  • 17
    • 8644281991 scopus 로고    scopus 로고
    • Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist
    • Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004 ; 47: 5995-6008
    • (2004) J Med Chem , vol.47 , pp. 5995-6008
    • Wan, Y.1    Wallinder, C.2    Plouffe, B.3
  • 18
    • 84871091482 scopus 로고    scopus 로고
    • Vicore Pharma accessed18 September 2012
    • Vicore Pharma, http://www.vicorepharma.com (2012, accessed18 September 2012).
    • (2012)
  • 19
    • 58149375072 scopus 로고    scopus 로고
    • Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?
    • Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?. Circulation. 2008 ; 118: 2523-2532
    • (2008) Circulation , vol.118 , pp. 2523-2532
    • Kaschina, E.1    Grzesiak, A.2    Li, J.3
  • 20
    • 84856479413 scopus 로고    scopus 로고
    • Direct stimulation of angiotensin II type 2 receptor enhances spatial memory
    • Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab. 2012 ; 32: 248-255
    • (2012) J Cereb Blood Flow Metab , vol.32 , pp. 248-255
    • Jing, F.1    Mogi, M.2    Sakata, A.3
  • 22
    • 84871034291 scopus 로고    scopus 로고
    • Spinifex Pharmaceuticals accessed 18 September 2012
    • Spinifex Pharmaceuticals, http://www.spinifexpharma.com.au (2012, accessed 18 September 2012).
    • (2012)
  • 23
    • 35349001774 scopus 로고    scopus 로고
    • Study of angiotensin-(1-7) vasoactive peptide and its β-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies
    • Lula I, Denadai AL, Resende JM, et al. Study of angiotensin-(1-7) vasoactive peptide and its β-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies. Peptides. 2007 ; 28: 2199-2210
    • (2007) Peptides , vol.28 , pp. 2199-2210
    • Lula, I.1    Denadai, A.L.2    Resende, J.M.3
  • 24
    • 84871075227 scopus 로고    scopus 로고
    • Derma Sciences accessed 18 September 2012
    • Derma Sciences, http://www.dermasciences.com/ (2012, accessed 18 September 2012).
    • (2012)
  • 25
    • 84871061590 scopus 로고    scopus 로고
    • Tarix Pharmaceuticals accessed 18 September 2012
    • Tarix Pharmaceuticals, http://www.tarixpharma.com (2012, accessed 18 September 2012).
    • (2012)
  • 26
    • 84863475958 scopus 로고    scopus 로고
    • NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial
    • Balingit PP, Armstrong DG, Reyzelman AM, et al. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen. 2012 ; 20: 482-490
    • (2012) Wound Repair Regen , vol.20 , pp. 482-490
    • Balingit, P.P.1    Armstrong, D.G.2    Reyzelman, A.M.3
  • 27
    • 58049193594 scopus 로고    scopus 로고
    • Discovery and validation of novel peptide agonists for G-protein-coupled receptors
    • Shemesh R, Toporik A, Levine Z, et al. Discovery and validation of novel peptide agonists for G-protein-coupled receptors. J Biol Chem. 2008 ; 283: 34643-34649
    • (2008) J Biol Chem , vol.283 , pp. 34643-34649
    • Shemesh, R.1    Toporik, A.2    Levine, Z.3
  • 28
    • 77953811506 scopus 로고    scopus 로고
    • Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor
    • Savergnini SQ, Beiman M, Lautner RQ, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension. 2010 ; 56: 112-120
    • (2010) Hypertension , vol.56 , pp. 112-120
    • Savergnini, S.Q.1    Beiman, M.2    Lautner, R.Q.3
  • 29
    • 84871039190 scopus 로고    scopus 로고
    • Compugen accessed 18 September 2012
    • Compugen, http://cgen.com (2007, accessed 18 September 2012).
    • (2007)
  • 30
    • 84871061282 scopus 로고    scopus 로고
    • accessed 18 September 2012
    • BioLineRx, http://www.biolinerx.com (2010, accessed 18 September 2012).
    • (2010) BioLineRx
  • 31
    • 0036900194 scopus 로고    scopus 로고
    • AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium
    • Wiemer G, Dobrucki LW, Louka FR, et al. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension. 2002 ; 40: 847-852
    • (2002) Hypertension , vol.40 , pp. 847-852
    • Wiemer, G.1    Dobrucki, L.W.2    Louka, F.R.3
  • 32
    • 84871044702 scopus 로고    scopus 로고
    • Apeiron Biologics accessed 18 September 2012
    • Apeiron Biologics, http://www.apeiron-biologics.com (2012, accessed 18 September 2012).
    • (2012)
  • 33
    • 42349105833 scopus 로고    scopus 로고
    • Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents
    • Prada JAH, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 ; 51: 1312-1317
    • (2008) Hypertension , vol.51 , pp. 1312-1317
    • Prada, J.A.H.1    Ferreira, A.J.2    Katovich, M.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.